此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

WATCHMAN FLX Pro 欧洲注册研究

2026年10月1日 更新者:Boston Scientific Corporation

WATCHMAN FLX Pro欧洲注册研究

The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.

研究概览

研究类型

观察性的

注册 (实际的)

189

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Aarhus、丹麦、8200
        • Aarhus University Hospital
      • Copenhagen、丹麦、2100
        • Rigshospitalet Copenhagen
      • Bad Oeynhausen、德国、32545
        • Herz-und Diabeteszentrum Nordrhein-Westfalen
      • Berlin、德国、12203
        • Charite, Campus Benjamin Franklin
      • Erfurt、德国、99097
        • Kath Krankenhaus St Johann Nepomuk
      • Hamburg、德国、22763
        • Asklepios Klinik Altona
      • Hamburg、德国、20099
        • Asklepios Klinik Saint Georg
      • Hamburg、德国、22417
        • Asklepios Klinik Nord Heidberg
      • Lübeck、德国、23582
        • Universitaetsklinikum Schleswig-Holstein
      • Catania、意大利、95123
        • Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco
      • Milan、意大利、20138
        • Centro Cardiologico Monzino
      • Verona、意大利、37126
        • Ospedale Sacro Cuore Don Calabria
      • Poznan、波兰、61-848
        • Uniwersytecki Szpital Kliniczny w Poznaniu
      • Basel、瑞士、4031
        • University Hospital Basel
      • Bern、瑞士、CH-3010
        • INSELSPITAL - Universitätsspital Bern
      • León、西班牙、24071
        • Hospital de Leon
      • Pamplona、西班牙、31008
        • Clinica Universidad de Navarra
      • Pontevedra、西班牙、36001
        • Complejo Hospitalario Universitario de Pontevedra
      • Pontevedra、西班牙、36001
        • Complejo Hospitalario de Pontevedra
      • Salamanca、西班牙、37007
        • Hospital Clinico Salamanca

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Hospital

描述

Inclusion Criteria:

  1. Subject is attempted to be treated with the WATCHMAN FLX™ Pro LAAC device.
  2. Subject has non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve) and is clinically indicated for a WATCHMAN FLX™ Pro LAAC device, per the Instructions for Use (IFU).
  3. Subject or legal representative who are willing and capable of providing informed consent.
  4. Subject is able and willing to return for required follow-up visits and examinations.
  5. Subject whose age is 18 years or above, or who is of legal age to give informed consent specific to state and national law.

Exclusion Criteria:

  1. Subject has a documented life expectancy of less than 12 months.
  2. Subject who is currently enrolled in another investigational study or registry except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments.
  3. Intracardiac thrombus is present.
  4. An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
  5. The LAA anatomy will not accommodate a Closure Device.
  6. Subject has a known hypersensitivity or contraindications according to IFU.
  7. Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
WATCHMAN FLX Pro

This arm is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device.

Approximately 300 patients undergo the LAAC procedure in conjunction with the use of the VersaCross Connect™ LAAC Access Solution.

The WATCHMAN FLX Pro LAAC Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in adult patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy.

The VersaCross Connect™ LAAC Access Solution is indicated for the percutaneous introduction of various types of cardiovascular catheters and guidewires to all heart chambers, including the left atrium via transseptal perforation / puncture.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of participants with a safety event treated with the WATCHMAN FLX Pro
大体时间:Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later

Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair.

Percutaneous catheter drainage of pericardial effusions, snaring of an embolized device, thrombin injection to treat femoral pseudoaneurysm and minor nonsurgical treatments of access site complications are excluded from this endpoint.

Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
Number of participants with a safety event treated with the VersaCross Connect™ LAAC Access Solution
大体时间:Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later

Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later:

For all enrolled subjects, who had an attempt to insert the VersaCross Connect™ LAAC Access Solution device, the composite rate of all-cause death, all stroke, systemic embolism, pericardial effusion resulting in interventions*, and ISTH major bleeding.

*Pericardial effusion/tamponade requiring pericardiocentesis or surgery to treat

Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
Number of participants with a successful VersaCross Connect™ LAAC Access Solution treatment
大体时间:Completion of transseptal puncture

VersaCross Connect™ LAAC Access Solution acute procedural success: Acute Procedural Success is defined as transseptal puncture success (VersaCross RF-wire crossing into left atrium).

Completion of transseptal puncture

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Arian Sultan, Prof. MD、Asklepios Klinik Saint Georg
  • 首席研究员:Marek Grygier, Prof. MD, PHD、Uniwersytecki Szpital Kliniczny w Poznaniu

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月17日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2028年9月1日

研究注册日期

首次提交

2025年11月17日

首先提交符合 QC 标准的

2025年11月21日

首次发布 (实际的)

2025年12月3日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • S2603

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅